Last reviewed · How we verify
PEDIACEL® and Prevenar®
PEDIACEL and Prevenar stimulate the immune system to produce antibodies against diphtheria, tetanus, pertussis, hepatitis B, and 13 serotypes of pneumococcal disease.
PEDIACEL and Prevenar stimulate the immune system to produce antibodies against diphtheria, tetanus, pertussis, hepatitis B, and 13 serotypes of pneumococcal disease. Used for Protection against diphtheria, tetanus, pertussis, hepatitis B, and 13 serotypes of pneumococcal disease in infants and young children, Prevention of invasive pneumococcal disease in infants and young children.
At a glance
| Generic name | PEDIACEL® and Prevenar® |
|---|---|
| Also known as | PEDIACEL®: DT5aP-IPV-Hib 5-component Pertussis vaccine, Prevenar®: Pneumococcal saccharide conj. vaccine, adsorbed |
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
PEDIACEL and Prevenar contain inactivated antigens from diphtheria, tetanus, pertussis, and pneumococcal bacteria, as well as hepatitis B surface antigen. These antigens are combined with adjuvants to enhance the immune response. The immune system recognizes the antigens as foreign and mounts an immune response, producing antibodies that can neutralize or remove the pathogens from the body.
Approved indications
- Protection against diphtheria, tetanus, pertussis, hepatitis B, and 13 serotypes of pneumococcal disease in infants and young children
- Prevention of invasive pneumococcal disease in infants and young children
Common side effects
- Injection site pain
- Fever
- Irritability
- Vomiting
- Diarrhea
Key clinical trials
- Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa (PHASE3)
- Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants (PHASE2)
- Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US (PHASE3)
- Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers (PHASE3)
- Vaccinating Children After Chemotherapy (PHASE4)
- Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers (PHASE3)
- Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers (PHASE3)
- Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PEDIACEL® and Prevenar® CI brief — competitive landscape report
- PEDIACEL® and Prevenar® updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI